Aspirin (NSC 27223)

Catalog No.S3017 Synonyms: Acetylsalicylic acid, ASA

For research use only.

Aspirin (NSC 27223, Acetylsalicylic acid, ASA) is a salicylate, and irreversible COX1 and COX2 inhibitor, used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin induces autophagy and stimulates mitophagy.

Aspirin (NSC 27223) Chemical Structure

CAS No. 50-78-2

Selleck's Aspirin (NSC 27223) has been cited by 20 publications

Purity & Quality Control

Choose Selective COX Inhibitors

Other COX Products

Biological Activity

Description Aspirin (NSC 27223, Acetylsalicylic acid, ASA) is a salicylate, and irreversible COX1 and COX2 inhibitor, used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin induces autophagy and stimulates mitophagy.
Targets
COX2 [1] COX1 [1]
In vitro

Aspirin inhibits the activation of NF-kappa B, thus prevents the degradation of the NF-kappa B inhibitor, I kappa B, and therefore NF-kappa B is retained in the cytosol. Aspirin also inhibits NF-kappa B-dependent transcription from the Ig kappa enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells. [1] Aspirin and salicylate are mediated in part by their specific inhibition of IKK-beta, thereby preventing activation by NF-kappaB of genes involved in the pathogenesis of the inflammatory response. [2] Aspirin is protective against neurotoxicity elicited by the excitatory amino acid glutamate in rat primary neuronal cultures and hippocampal slices. [3] Aspirin triggers transcellular biosynthesis of a previously unrecognized class of eicosanoidsduring coincubations of human umbilical vein endothelial cells (HUVEC) and neutrophils [polymorphonuclear leukocytes (PMN)]. Aspirin evokes a unique class of eicosanoids formed by acetylated PGHS-2 and 5-lipoxygenase interactions. [4] Aspirin treatment inhibits the phosphorylation of IRS-1 at Ser307 as well as the phosphorylation of JNK, c-Jun, and degradation of IkappaBalpha in 3T3-L1 and Hep G2 cells treated with tumor necrosis factor (TNF)-alpha. Aspirin treatment inhibits phosphorylation of Akt and the mammalian target of rapamycin (but not extracellular regulated kinase or PKCzeta) in response to TNF-alpha. Aspirin rescues insulin-induced glucose uptake in 3T3-L1 adipocytes pretreated with TNF-alpha. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
AGS M3XPdWZ2dmO2aX;uJIF{e2G7 M{PtUlE2KHSxIE[wJJVud2xxTDDh[pRmeg>? NFz3O5UyOiCqcoO= NWfW[lJHUW6qaXLpeIlwdiCxZjDFd4Np\XKrY3jpZUBkd2yrLYP0bY12dGG2ZXSgTWwuQCCycn;keYN1cW:wIHnuJIh2dWGwIFHHV{Bk\WyuczDheEAyPSC2bzC2NEB2dW:uL1ygZYZ1\XJiMUKgbJJ{KGK7IFXMTXNC MlXBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNUOxPFMoRjJyMUWzNVg{RC:jPh?=
microglia cells M{XpW2FvfGmwZYXyc4lv\myjbX3heI9zgSCjc4PhfS=> MUGxOUBucW6| Mn\QRY51cW6ndYLvbY5ndGGvbXH0c5J6KGGldHn2bZR6KGmwIFzQV{1{fGmvdXzheIVlKHKjdDDtbYNzd2euaXGgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCSTVGtd5RqdXWuYYTl[EBVYEJ{IILlcIVie2VicILlbY5kfWKjdHXkJIZweiBzNTDtbY5{KG2nYYP1doVlKDdyIH3pcpMh[W[2ZYKgVG1CKGOqYXzs[Y5o\SxiSVO1NF0{NjF{zszN NGWzNWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG1N|g4PCd-MkKxOVM5PzR:L3G+
HCT116 M3;V[2Z2dmO2aX;uJIF{e2G7 M3;Ie|EhdU1? NIraOGk3KGi{cx?= NXTK[oNxUW6qaXLpeIlwdiCxZjDUUmYu[WyyaHGtbY5lfWOnZDDOSk1s[XCyYVKgZYN1cX[jdHnvckBqdiCqdX3hckBJS1RzMU[gZ4VtdHNiYYSgNUBuVSCjZoTldkA3KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[Xl? MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF3NEizOEc,OjJzNUS4N|Q9N2F-
SKBR3 M1XUSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVWzNFAhfU1? MYC0PEBpenN? NW\VZ5M3T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW0uEUkOgZ4VtdHNiYYSgN|AxKHWPIHHmeIVzKDR6IHjyd{BjgSCjbHHtZZIh[my3ZTDhd5NigQ>? MoPiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2OUS2NVcoRjJ{NEm0OlE4RC:jPh?=
PANC1 MnruS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1XzNFMxOCC3TR?= MXW0PEBpenN? M1\TTWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHBCVkNzIHPlcIx{KGG2IEOwNEB2VSCjZoTldkA1QCCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZk> NYC5cJZwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0PVQ3OTdpPkKyOFk1PjF5PD;hQi=>
PC3 M4PBeGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXr6eYtxOzByIIXN NVjUPJlHPDhiaILz M4X4fGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHBEOyClZXzsd{BifCB|MECgeW0h[W[2ZYKgOFghcHK|IHL5JIFt[W2jcjDicJVmKGG|c3H5 NYLnWJN[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0PVQ3OTdpPkKyOFk1PjF5PD;hQi=>
MDA-MB-231 MUTGeY5kfGmxbjDhd5NigQ>? Mmf4NVAxKHWP NHHjWJo{OCCvaX7z MlK1TZJz\X[ncoPpZoxmKGmwaHnibZRqd25ib3[gR29ZNTFiaX6gbJVu[W5iTVTBMW1DNTJ|MTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGG{YXPobYRwdmmlIHHjbYQucW6mdXPl[EBRT0V{IH\vdo1ifGmxbjDheEAyODBidV2gbY5kfWKjdHXkJIZweiB|MDDtbY5{KG[xbHzve4VlKGK7IHPvcZBwfW6mIIfhd4hwfXRibXXhd5Vz\WRiM{CgcYlveyCyb4P0JIFz[WOqaXTvcolkKGGlaXSgZ4hidGynbnflJIJ6KHKjZHnvbY1ufW6xYYPzZZk> NXrhNY5vRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2OVE{PTlpPkKzOlUyOzV7PD;hQi=>
THP1 MlHISpVv[3Srb36gZZN{[Xl? NHTB[VUyODBidV2= MUGzNEBucW6| NXrtVIR{UXK{ZY\ldpNq[mynIHnubIljcXSrb36gc4YhS0:[LUGgbY4hcHWvYX6gWGhROSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJIFz[WOqaXTvcolkKGGlaXStbY5lfWOnZDDUXGIzKG[xcn3heIlwdiCjdDCxNFAhfU1iaX7jeYJifGWmIH\vdkA{OCCvaX7zJIZwdGyxd3XkJIJ6KGOxbYDveY5lKHejc3jveZQhdWWjc4Xy[YQhOzBibXnud{Bxd3O2IHHyZYNpcWSxbnnjJIFkcWRiY3jhcIxmdmenIHL5JJJi\GmxaX3teY5w[XO|YYm= M3XoUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkWxN|U6Lz5{M{[1NVM2QTxxYU6=
HCT116 NHLPWGlEgXSxdH;4bYNqfHliYYPzZZk> NYPGTWxjPDhiaILz M2fub2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDFzNjDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZYZ1\XJiNEigbJJ{KE2WVDDhd5NigQ>? MnXGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5NUC0NFEoRjJ4N{WwOFAyRC:jPh?=
H9c2 M1PWb2NiemSrb4Dyc5Rm[3SrdnWgZZN{[Xl? MWGxJJVO M4Xkd|ghcHK| MYrDZZJlcW:ycn;0[YN1cX[nIHHjeIl3cXS7IHHnZYlve3RiaInwc5hq[S2rbnT1Z4VlKG:6aXTheIl3\SC|dILld5MhdWWmaXH0[YQhcW6obHHtcYF1cW:wIHnuJJJifCCKOXOyJINmdGy|IHHzd4V{e2WmIHHzJJN2eHC{ZYPzbY9vKG:oIFnMMVYhcW5ic4Xw[ZJv[XSjboSgZZQhOSC3TTDwdoVqdmO3YnH0[YQh\m:{IEigbJJ{KG[xbHzve4VlKGK7IFiyU|Ih[WSmaYTpc44h\m:{IEKgbJJ{KGK7IFXMTXNC MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzV5NUS3NUc,Ojd3N{W0O|E9N2F-
H9c2 NUjkemR{S2G{ZHnvdJJwfGWldHn2[UBie3OjeR?= NGTRXGsyKHWP NFXCWI85KGi{cx?= NHW3cWRE[XKmaX;wdo91\WO2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJlxd3irYT3pcoR2[2WmIH;4bYRifGm4ZTDzeJJme3NibXXkbYF1\WRiaX7mcIFudWG2aX;uJIlvKHKjdDDIPYMzKGOnbHzzJIF{e2W|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJHRPTi2jbIDoZUBqdiC|dYDldo5ifGGwdDDheEAyKHWPIIDy[Ylv[3WkYYTl[EBnd3JiODDodpMh\m:ubH;3[YQh[nliSELPNkBi\GSrdHnvckBnd3JiMjDodpMhcW5icILld4Vv[2Vib3[gcIVwdnW{aX7lJIJ6KEV? MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzV5NUS3NUc,Ojd3N{W0O|E9N2F-
H9c2 MmDiR4Fz\GmxcILveIVkfGm4ZTDhd5NigQ>? MVmxJJVO NILWdHM5KGi{cx?= M4Dp[GNiemSrb4Dyc5Rm[3SrdnWgZYN1cX[rdImgZYdicW6|dDDofZBwgGmjLXnu[JVk\WRib4jp[IF1cX[nIIP0doV{eyCrbjDyZZQhUDmlMjDj[YxteyCjc4Pld5Nm\CCjczDhcpRqd3irZHHueEBi[3Srdnn0fUBjgSCvZXHzeZJqdmdicnXkeYN1cW:wIHnuJG1FSSCuZY\lcJMh[XRiMTD1UUBxemWrbnP1ZoF1\WRiZn;yJFghcHK|IH\vcIxwf2WmIHL5JGgzVzJiYXTkbZRqd25iZn;yJFIhcHK|IHL5JJNx\WO2cn;wbI91d22ndIL5 MmSwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd3N{W0O|EoRjJ5NUe1OFcyRC:jPh?=
H9c2 Mn64R4Fz\GmxcILveIVkfGm4ZTDhd5NigQ>? NXf2T5NbOSC3TR?= NIW2Sno5KGi{cx?= NX3SblFyS2G{ZHnvdJJwfGWldHn2[UBi[3Srdnn0fUBi\2GrboP0JIh6eG:6aXGtbY5lfWOnZDDvfIll[XSrdnWgd5Rz\XO|IHnuJJJifCCKOXOyJINmdGy|IHHzd4V{e2WmIHHzJIFvfGmxeHnkZY51KGGldHn2bZR6KGK7IH3lZZN2emmwZzDpcoNz\WG|ZTDpckBUV0RiYXP0bZZqfHliYYSgNUB2VSCycnXpcoN2[mG2ZXSg[o9zKDhiaILzJIZwdGyxd3XkJIJ6KEh{T{KgZYRlcXSrb36g[o9zKDJiaILzJIJ6KHOyZXP0do9xcG:2b33leJJ6 MnTJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd3N{W0O|EoRjJ5NUe1OFcyRC:jPh?=
H9c2 NFT0TYdE[XKmaX;wdo91\WO2aY\lJIF{e2G7 NG\pd|IyKHWP M2XRXFghcHK| NGXGVYVE[XKmaX;wdo91\WO2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJlxd3irYT3pcoR2[2WmIH;4bYRifGm4ZTDzeJJme3NiaX6gdoF1KEh7Y{KgZ4VtdHNiYYPz[ZN{\WRiYYOgZY51cW:6aXThcpQh[WO2aY\peJkh[nlibXXhd5VzcW6pIHnuZ5Jm[XOnIHnuJINifGGuYYPlJIFkfGm4aYT5JIF1KDFidV2gdJJmcW6ldXLheIVlKG[xcjC4JIhzeyCob3zsc5dm\CCkeTDINm8zKGGmZHn0bY9vKG[xcjCyJIhzeyCkeTDzdIVkfHKxcHjveI9u\XS{eR?= MliyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd3N{W0O|EoRjJ5NUe1OFcyRC:jPh?=
H9c2 NWnqbVFnS2G{ZHnvdJJwfGWldHn2[UBie3OjeR?= MUSxJJVO NFXlfmw5KGi{cx?= M3HVcmNiemSrb4Dyc5Rm[3SrdnWgZYN1cX[rdImgZYdicW6|dDDofZBwgGmjLXnu[JVk\WRib4jp[IF1cX[nIIP0doV{eyCvZXTpZZRm\CCrbn\sZY1u[XSrb36gbY4hemG2IFi5Z|Ih[2WubIOgZZN{\XO|ZXSgZZMhe3WycILld5Nqd25ib3[gWG5HNWGucHjhJIlvKHO3cHXycoF1[W62IHH0JFEhfU1icILlbY5kfWKjdHXkJIZweiB6IHjyd{Bnd2yub4fl[EBjgSCKMl:yJIFl\Gm2aX;uJIZweiB{IHjyd{BjgSCHTFnTRS=> MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzV5NUS3NUc,Ojd3N{W0O|E9N2F-
H9c2 MY\DZZJlcW:ycn;0[YN1cX[nIHHzd4F6 NUj0fVIyOSC3TR?= Mm\nPEBpenN? NH;BfIZE[XKmaX;wdo91\WO2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJlxd3irYT3pcoR2[2WmIH;4bYRifGm4ZTDzeJJme3NibXXkbYF1\WRiaX7mcIFudWG2aX;uJIlvKHKjdDDIPYMzKGOnbHzzJIF{e2W|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJGlNNTGkZYThJIlvKHO3cHXycoF1[W62IHH0JFEhfU1icILlbY5kfWKjdHXkJIZweiB6IHjyd{Bnd2yub4fl[EBjgSCKMl:yJIFl\Gm2aX;uJIZweiB{IHjyd{BjgSCHTFnTRS=> NH;Xc2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{W3OVQ4OSd-Mke1O|U1PzF:L3G+
H9c2 MYHDZZJlcW:ycn;0[YN1cX[nIHHzd4F6 NVzwTmwzOSC3TR?= MkHuPEBpenN? MkfxR4Fz\GmxcILveIVkfGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj5dI95cWFvaX7keYNm\CCxeHnkZZRqfmVic4Ty[ZN{KGmwIILheEBJQWN{IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBOTEFibHX2[Yx{KGG2IEGgeW0heHKnaX7jeYJifGWmIH\vdkA5KGi{czDmc4xtd3enZDDifUBJOk9{IHHk[Il1cW:wIH\vdkAzKGi{czDpckBxemW|ZX7j[UBw\iCuZX;ueZJqdmViYomgd5Bm[3S{b4Doc5RwdWW2com= NUjDTW9RRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke1O|U1PzFpPkK3OVc2PDdzPD;hQi=>
H9c2 MmnPR4Fz\GmxcILveIVkfGm4ZTDhd5NigQ>? MoTtNUB2VQ>? MYG4JIhzew>? NFzWVJlE[XKmaX;wdo91\WO2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJlxd3irYT3pcoR2[2WmIH;4bYRifGm4ZTDzeJJme3NiaX6gdoF1KEh7Y{KgZ4VtdHNiYYPz[ZN{\WRiYYOgZY51cW:6aXThcpQh[WO2aY\peJkh[nlibXXhd5VzcW6pIHnuZ5Jm[XOnIHnuJHNQTCCjY4Tpeol1gSCjdDCxJJVOKHC{ZXnuZ5Vj[XSnZDDmc5IhQCCqcoOg[o9tdG:5ZXSgZpkhUDKRMjDh[IRqfGmxbjDmc5IhOiCqcoOgbY4heHKnc3XuZ4Uhd2ZibHXvcpVzcW6nIHL5JJNx\WN? M2i0c|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NUe1OFcyLz5{N{W3OVQ4OTxxYU6=
H9c2 NW\ldXRYS2G{ZHnvdJJwfGWldHn2[UBie3OjeR?= M2TCVlEhfU1? NF3YPWk5KGi{cx?= NVi4NI14S2G{ZHnvdJJwfGWldHn2[UBi[3Srdnn0fUBi\2GrboP0JIh6eG:6aXGtbY5lfWOnZDDvfIll[XSrdnWgd5Rz\XO|IH3l[IlifGWmIHnu[oxidW2jdHnvckBqdiC{YYSgTFlkOiClZXzsd{Bie3Onc4Pl[EBieyC|dYDwdoV{e2mxbjDv[kBKVC14IHnuJJN2eGW{bnH0ZY51KGG2IEGgeW0heHKnaX7jeYJifGWmIH\vdkA5KGi{czDmc4xtd3enZDDifUBJOk9{IHHk[Il1cW:wIH\vdkAzKGi{czDpckBxemW|ZX7j[UBw\iCuZX;ueZJqdmViYomgSWxKW0F? M2HSfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NUe1OFcyLz5{N{W3OVQ4OTxxYU6=
H9c2 MkXOR4Fz\GmxcILveIVkfGm4ZTDhd5NigQ>? NVjHOplDOSC3TR?= MVW4JIhzew>? M1W3OWNiemSrb4Dyc5Rm[3SrdnWgZYN1cX[rdImgZYdicW6|dDDofZBwgGmjLXnu[JVk\WRib4jp[IF1cX[nIIP0doV{eyCvZXTpZZRm\CCrbn\sZY1u[XSrb36gbY4hemG2IFi5Z|Ih[2WubIOgZZN{\XO|ZXSgZZMhe3WycILld5Nqd25ib3[gTWwuOWKndHGgbY4he3WyZYLuZZRidnRiYYSgNUB2VSCycnXpcoN2[mG2ZXSg[o9zKDhiaILzJIZwdGyxd3XkJIJ6KEh{T{KgZYRlcXSrb36g[o9zKDJiaILzJIlvKHC{ZYPlcoNmKG:oIHzlc452emmwZTDifUBGVA>? M3HKfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NUe1OFcyLz5{N{W3OVQ4OTxxYU6=
H9c2 MWXDZZJlcW:ycn;0[YN1cX[nIHHzd4F6 MVexJJVO MUG4JIhzew>? M3jIOmNiemSrb4Dyc5Rm[3SrdnWgZYN1cX[rdImgZYdicW6|dDDofZBwgGmjLXnu[JVk\WRiY4n0c5RwgGmlaYT5JIlvKHKjdDDIPYMzKGOnbHzzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGG2IEGgeW0heHKnaX7jeYJifGWmIH\vdkA5KGi{czDmc4xtd3enZDDifUBJOk9{IHHk[Il1cW:wIH\vdkAzKGi{czDifUBOXFRiYYPzZZk> NYe4UHhxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke1O|U1PzFpPkK3OVc2PDdzPD;hQi=>
RAW264.7 NVvRZ4ZrSW62aXnu[oxidW2jdH;yfUBie3OjeR?= NUjvfGFkSW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBqdiCvb4Xz[UBTSVd{NkSuO{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFzQV{1qdmS3Y3XkJI5qfHKrYzDvfIll\SCycn;keYN1cW:wIHL5JI1m[XO3cnnu[{BvcXS{aYTlJIFk[3WvdXzheIlwdiCkeTDHdolme3NibXX0bI9lNCCLQ{WwQVQ{NjMQvF2= NYHwO45YRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1OlE2QDZpPkK4OVYyPTh4PD;hQi=>
stem cells MkX5SpVv[3Srb36gZZN{[Xl? M{HPUVExOCC3TR?= MVe1JIRigXN? NGSyPHdKdmS3Y4Tpc44hd2ZiYXTpdI9o\W6nc3nzJIlvKGi3bXHuJIJwdmVibXHydo94NWSncnn2[YQhdWW|ZX7jbJlu[Wxic4TlcUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCjZHnwc45m[3SrbjDwdo9lfWO2aX;uJIF1KDFyMDD1UUBu\WG|dYLl[EBwdiCmYYmgOUBqdiCycnXz[Y5k\SCxZjDJSHgh[nliRVzJV2E> MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTN7OES0N{c,Ojl|OUi0OFM9N2F-
DAOY M4PLepFJXFNiYYPzZZk> M4PSV5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCGQV;ZJINmdGy| NUTZWIF{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh30 M1:zepFJXFNiYYPzZZk> MnPUdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqM{CgZ4VtdHN? M2n3N|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41 NWi3RmFDeUiWUzDhd5NigQ>? Mn\hdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqNEGgZ4VtdHN? MmjIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
peritoneal cells MojPSpVv[3Srb36gZZN{[Xl? NFLhTIs2KGi{cx?= MVXJcohq[mm2aX;uJI9nKEySUz3pcoR2[2WmIGDHSVIheHKxZIXjeIlwdiCrbjDDOVdDVDZibX;1d4UheGW{aYTvcoVidCClZXzsd{Bu\WG|dYLl[EBifCB3IHjyd{B1cW2nIHnueIVzfmGuIHL5JGVNUVODLDDJR|UxRTRwMElOwG0> M2SzSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEC2NVczLz5|MECwOlE4OjxxYU6=
HCT8 NFPCT|NCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MXG3NkBpenN? NGnXWFVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFgh[2WubIOgZYZ1\XJiN{KgbJJ{KGmwIIDy[ZNmdmOnIH;mJINqdm6jbXHs[IVpgWSnIHL5JG1VXCCjc4PhfUwhUUN3ME2xOU43|ryP MoT2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByM{e0PVQoRjNyMEO3OFk1RC:jPh?=
RPMI8226 NFXoOHFE\WyuIHP5Z4xmKGG|c3H5 MUCxMlchfU1? NFfDWpo1QCCqcoO= NFzhNGVE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBTWE2LOEKyOkBk\WyuczDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgS|AwTzFicHjhd4Uh[XRiMT63JJVOKGmwIIDy[ZNmdmOnIH;mJIJwenSnen;tbYIh[W[2ZYKgOFghcHK|IHL5JJBzd3CrZHn1cUBqd2SrZHWvVm5ie2Vic4ThbY5qdmdiYnHz[YQh\myxdzDjfZRwdWW2cnnjJI1mfGixZDDy[YxifGm4ZTD0c{Bjd3K2ZYrvcYlj M1LLd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNUmwNlU5Lz5|MEW5NFI2QDxxYU6=
RPMI8226 M1e3TWNmdGxiY4njcIUh[XO|YYm= M13aeFEvPyC3TR?= MmjZOFghcHK| NHrVfGpE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBTWE2LOEKyOkBk\WyuczDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgV{BxcGG|ZTDheEAyNjdidV2gbY4heHKnc3XuZ4Uhd2ZiYn;yeIV7d22rYjDh[pRmeiB2ODDodpMh[nlicILvdIllcXWvIHnv[Ill\S:UTnHz[UB{fGGrbnnu[{Bj[XOnZDDmcI94KGO7dH;t[ZRzcWNibXX0bI9lKHKnbHH0bZZmKHSxIHLvdpRmgm:vaXK= M3n4e|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNUmwNlU5Lz5|MEW5NFI2QDxxYU6=
RPMI8226 M{XMNmNmdGxiY4njcIUh[XO|YYm= MUixMlchfU1? MmixOFghcHK| NVvsd2duS2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hWlCPSUiyNlYh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHHjZ5VufWyjdHnvckBifCCJMj;NJJBp[XOnIHH0JFEvPyC3TTDpckBxemW|ZX7j[UBw\iCkb4L0[ZpwdWmkIHHmeIVzKDR6IHjyd{BjgSCycn;wbYRqfW1iaX;kbYRmN1KQYYPlJJN1[WmwaX7nJIJie2WmIH\sc5ch[3m2b33leJJq[yCvZYToc4QhemWuYYTpeoUhfG9iYn;yeIV7d22rYh?= MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODV7MEK1PEc,OzB3OUCyOVg9N2F-
HaCaT NUPTV5hxSW62aYD5doV1cWNiYYPzZZk> NF\2[GsyODBidV2= NGDsSmgzKGi{cx?= NWLhe41USW62aYD5doV1cWNiYXP0bZZqfHliaX6gbJVu[W5iSHHDZXQh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDUUmZidHCqYT3pcoR2[2WmIGDHSVIheHKxZIXjeIlwdiCjdDCxNFAhfU1icILlMYlv[3WkYYTl[EBnd3JiMjDodpMh[mWob4LlJHRPTmGucHjhJJN1cW23bHH0bY9vKG[xcjCyOEBpenNiYomgSWxKW0F? Mlf6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzF|OUOxNlUoRjNzM{mzNVI2RC:jPh?=
OVCAR5 MVrGeY5kfGmxbjDhd5NigQ>? MkDvN|AxKHWPIITvJFEhdU1? Mn3lO|IhcHK| M3PkU2lvcGmkaYTpc44hd2ZiTlHQVnQhcW5iaIXtZY4hV1[FQWK1JINmdGy|IHHzd4V{e2WmIHHzJJBwfGWwdHnheIlwdiCxZjDORW1RXCCrbnjpZol1d3JiRlu4OlYucW6mdXPl[EBkgXSxdH;4bYNqfHliYomgcYVie3W{aX7nJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBifCB|MECgeW0hfG9iMTDtUUBqdmO3YnH0[YQh\m:{IEeyJIhzeyCkeTDTVmIh[XO|YYm= M2\ve|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2Nyd-Q3jFUWJNRC:jPh?=
CCRF-CEM M4jnOGZ2dmO2aX;uJIF{e2G7 M17YVlMvPSCvTR?= MWG0PEBpenN? MoXETY5pcWKrdHnvckBw\iCQQWDSWEBqdiCqdX3hckBES1KILVPFUUBk\WyuczDhd5Nme3OnZDDhd{Bxd3SnboTpZZRqd25ib3[gUmFOWFRiaX7obYJqfG:{IF\LPFY3NWmwZIXj[YQh[XCxcITvd4l{KGK7IH3lZZN2emmwZzDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZZQhOy53IH3NJJBz\XJvaX7jeYJifGWmIIfpeIghUUN3MDDs[ZZmdCCxZjDGT|g3PiCob4KgOFghcHK|IH\vcIxwf2WmIHL5JINwdXCxdX7kJIFl\Gm2aX;uJIFv\CCodYL0bIVz M4nIXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2Nyd-Q3jFUWJNRC:jPh?=
Jurkat MVPGeY5kfGmxbjDhd5NigQ>? NXO3VYdzOy53IH3N NHLPU2U1QCCqcoO= NXfkeI9QUW6qaXLpeIlwdiCxZjDORXBTXCCrbjDoeY1idiCMdYLrZZQh[2WubIOgZZN{\XO|ZXSgZZMheG:2ZX70bYF1cW:wIH;mJG5CVVCWIHnubIljcXSxcjDGT|g3Pi2rbnT1Z4VlKGGyb4D0c5NqeyCkeTDt[YF{fXKrbnegdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIF1KDNwNTDtUUBxemW{LXnuZ5Vj[XSnZDD3bZRpKEmFNUCgcIV3\Wxib3[gSms5PjZiZn;yJFQ5KGi{czDmc4xtd3enZDDifUBkd22yb4Xu[EBi\GSrdHnvckBidmRiZoXyeIhmeiCr NIDBWlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPS9pPlPoSW1DVDxxYU6=
ML2 MonsSpVv[3Srb36gZZN{[Xl? NX34WpA5Oy53IH3N MnLBOFghcHK| NFHDeYFKdmirYnn0bY9vKG:oIF7BVHJVKGmwIHj1cYFvKE2OMjDj[YxteyCjc4Pld5Nm\CCjczDwc5RmdnSrYYTpc44hd2ZiTlHNVHQhcW6qaXLpeI9zKE[NOE[2MYlv\HWlZXSgZZBweHSxc3nzJIJ6KG2nYYP1dolv\yC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYYSgN{42KG2PIIDy[ZIucW6ldXLheIVlKHerdHigTWM2OCCuZY\lcEBw\iCIS{i2OkBnd3JiNEigbJJ{KG[xbHzve4VlKGK7IHPvcZBwfW6mIHHk[Il1cW:wIHHu[EBnfXK2aHXyJIlv[3V? NHjtOGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPS9pPlPoSW1DVDxxYU6=
NOMO MWfGeY5kfGmxbjDhd5NigQ>? NWTrbVVnOy53IH3N M3zPTlQ5KGi{cx?= MmC4TY5pcWKrdHnvckBw\iCQQWDSWEBqdiCqdX3hckBPV02RIHPlcIx{KGG|c3Xzd4VlKGG|IIDveIVvfGmjdHnvckBw\iCQQV3QWEBqdmirYnn0c5IhTkt6Nk[tbY5lfWOnZDDhdI9xfG:|aYOgZpkhdWWjc4XybY5oKHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjdDCzMlUhdU1icILldk1qdmO3YnH0[YQhf2m2aDDJR|UxKGyndnXsJI9nKE[NOE[2JIZweiB2ODDodpMh\m:ubH;3[YQh[nliY3;tdI92dmRiYXTkbZRqd25iYX7kJIZ2enSqZYKgbY5k NV3CUVVXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjVxJ{7DbGVOSkx:L3G+
NB4 M4LjNWZ2dmO2aX;uJIF{e2G7 Mk\qN{42KG2P M1vNU|Q5KGi{cx?= MmTuTY5pcWKrdHnvckBw\iCQQWDSWEBqdiCqdX3hckBPSjRiY3XscJMh[XO|ZYPz[YQh[XNicH;0[Y51cWG2aX;uJI9nKE6DTWDUJIlvcGmkaYTvdkBHUzh4Nj3pcoR2[2WmIHHwc5B1d3OrczDifUBu\WG|dYLpcochemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGG2IEOuOUBuVSCycnXyMYlv[3WkYYTl[EB4cXSqIFnDOVAhdGW4ZXygc4YhTkt6Nk[g[o9zKDR6IHjyd{Bnd2yub4fl[EBjgSClb33wc5Vv\CCjZHTpeIlwdiCjbnSg[pVzfGincjDpcoN2 MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOU8oRkOqRV3CUFww[T5?
NAMALWA NVXIWG1xTnWwY4Tpc44h[XO|YYm= NEHiZVI{NjVibV2= Mn[yOFghcHK| NVTiPZJyUW6qaXLpeIlwdiCxZjDORXBTXCCrbjDoeY1idiCQQV3BUHdCKGOnbHzzJIF{e2W|c3XkJIF{KHCxdHXueIlifGmxbjDv[kBPSU2SVDDpcohq[mm2b4KgSms5PjZvaX7keYNm\CCjcH;weI9{cXNiYomgcYVie3W{aX7nJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBifCB|LkWgcW0heHKncj3pcoN2[mG2ZXSge4l1cCCLQ{WwJIxmfmWuIH;mJGZMQDZ4IH\vdkA1QCCqcoOg[o9tdG:5ZXSgZpkh[2:vcH;1coQh[WSmaYTpc44h[W6mIH\1dpRp\XJ? MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOU8oRkOqRV3CUFww[T5?
Daudi NVzHWWNzTnWwY4Tpc44h[XO|YYm= M2DwRVMvPSCvTR?= MkXXOFghcHK| M{O3OmlvcGmkaYTpc44hd2ZiTlHQVnQhcW5iaIXtZY4hTGG3ZHmgZ4VtdHNiYYPz[ZN{\WRiYYOgdI91\W62aXH0bY9vKG:oIF7BUXBVKGmwaHnibZRweiCIS{i2Ok1qdmS3Y3XkJIFxd3C2b4Ppd{BjgSCvZXHzeZJqdmdicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHH0JFMvPSCvTTDwdoVzNWmwY4XiZZRm\CC5aYToJGlEPTBibHX2[Ywhd2ZiRlu4OlYh\m:{IES4JIhzeyCob3zsc5dm\CCkeTDjc41xd3WwZDDh[IRqfGmxbjDhcoQh\nW{dHjldkBqdg>? MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOU8oRkOqRV3CUFww[T5?
Raji NI\QN5hHfW6ldHnvckBie3OjeR?= NVfoZW97Oy53IH3N NHjjTG41QCCqcoO= NIKwVGZKdmirYnn0bY9vKG:oIF7BVHJVKGmwIHj1cYFvKFKjanmgZ4VtdHNiYYPz[ZN{\WRiYYOgdI91\W62aXH0bY9vKG:oIF7BUXBVKGmwaHnibZRweiCIS{i2Ok1qdmS3Y3XkJIFxd3C2b4Ppd{BjgSCvZXHzeZJqdmdicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHH0JFMvPSCvTTDwdoVzNWmwY4XiZZRm\CC5aYToJGlEPTBibHX2[Ywhd2ZiRlu4OlYh\m:{IES4JIhzeyCob3zsc5dm\CCkeTDjc41xd3WwZDDh[IRqfGmxbjDhcoQh\nW{dHjldkBqdmN? NFXxems9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPS9pPlPoSW1DVDxxYU6=
ARH77 MWHGeY5kfGmxbjDhd5NigQ>? M1PGeFMvPSCvTR?= M4P4dFQ5KGi{cx?= Ml;1TY5pcWKrdHnvckBw\iCQQWDSWEBqdiCqdX3hckBCWkh5NzDj[YxteyCjc4Pld5Nm\CCjczDwc5RmdnSrYYTpc44hd2ZiTlHNVHQhcW6qaXLpeI9zKE[NOE[2MYlv\HWlZXSgZZBweHSxc3nzJIJ6KG2nYYP1dolv\yC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYYSgN{42KG2PIIDy[ZIucW6ldXLheIVlKHerdHigTWM2OCCuZY\lcEBw\iCIS{i2OkBnd3JiNEigbJJ{KG[xbHzve4VlKGK7IHPvcZBwfW6mIHHk[Il1cW:wIHHu[EBnfXK2aHXyJIlv MkLtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlUwLz6FaFXNRmw9N2F-
RPMI8226 NUi3[4VGTnWwY4Tpc44h[XO|YYm= NULQd2tpOy53IH3N M3r2U|Q5KGi{cx?= M1fST2lvcGmkaYTpc44hd2ZiTlHQVnQhcW5iaIXtZY4hWlCPSUiyNlYh[2WubIOgZZN{\XO|ZXSgZZMheG:2ZX70bYF1cW:wIH;mJG5CVVCWIHnubIljcXSxcjDGT|g3Pi2rbnT1Z4VlKGGyb4D0c5NqeyCkeTDt[YF{fXKrbnegdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIF1KDNwNTDtUUBxemW{LXnuZ5Vj[XSnZDD3bZRpKEmFNUCgcIV3\Wxib3[gSms5PjZiZn;yJFQ5KGi{czDmc4xtd3enZDDifUBkd22yb4Xu[EBi\GSrdHnvckBidmRiZoXyeIhmeg>? NXjFcINSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjVxJ{7DbGVOSkx:L3G+
U266 NWnrfFh7TnWwY4Tpc44h[XO|YYm= MofuN{42KG2P NGToNW01QCCqcoO= M{LuWWlvcGmkaYTpc44hd2ZiTlHQVnQhcW5iaIXtZY4hXTJ4NjDj[YxteyCjc4Pld5Nm\CCjczDwc5RmdnSrYYTpc44hd2ZiTlHNVHQhcW6qaXLpeI9zKE[NOE[2MYlv\HWlZXSgZZBweHSxc3nzJIJ6KG2nYYP1dolv\yC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYYSgN{42KG2PIIDy[ZIucW6ldXLheIVlKHerdHigTWM2OCCuZY\lcEBw\iCIS{i2OkBnd3JiNEigbJJ{KG[xbHzve4VlKGK7IHPvcZBwfW6mIHHk[Il1cW:wIHHu[EBnfXK2aHXyJIlv[w>? NGfwTnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPS9pPlPoSW1DVDxxYU6=
NAMALWA NHvjXoJHfW6ldHnvckBie3OjeR?= M4m1S|M2KG2pL3vn M{[0blQ2KGSjeYO= M3zp[XBwfGWwdHnheIlwdiCxZjDORW1RXCCrbnjpZol1d3JiMUCgcYcwc2duIHnwJIJq\CCIS{i2Ok1qdmS3Y3XkJIFvfGm2dX3vdkBi[3Srdnn0fUBqdiCqdX3hckBPSU2DTGfBJINmdGy|IIjlco9oemGodHXkJIlvKFOFSVSgcY92e2ViYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hdW:3c3Wgd5Vzfmm4YXygZZQhOzVibXevb4ctKGmyIHLp[EB2eCC2bzC0OUBl[Xm| MofuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlUwLz6FaFXNRmw9N2F-
Assay
Methods Test Index PMID
Western blot SHH / SMO / GLI1 / Bcl-2 / Foxm1 ; ; p-AMPKα / AMPKα / p-ACC / ACC ; p-AKT / AKT / p-ERK / ERK ; MCL-1 28446712 23741443 26918349
Growth inhibition assay Cell viability ; Cell proliferation 30221683 28446712

Protocol (from reference)

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
4% DMSO+PBS
For best results, use promptly after mixing.

10mg/mL

Chemical Information

Molecular Weight 180.16
Formula

C9H8O4

CAS No. 50-78-2
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(=O)OC1=CC=CC=C1C(=O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04563546 Not yet recruiting Other: Quality Improvement Acute Coronary Syndrome Duke University January 1 2023 Not Applicable
NCT05031455 Not yet recruiting Biological: Dupilumab|Drug: Placebo Aspirin-exacerbated Respiratory Disease Scripps Clinic|University of California San Diego|Regeneron Pharmaceuticals January 1 2022 Phase 2
NCT05166096 Recruiting Drug: Rho-11|Drug: aspirin 325mg Healthy Rhoshan Pharmaceuticals Inc December 3 2021 Phase 1
NCT04308551 Not yet recruiting Drug: Indobufen|Drug: Aspirin Stable Coronary Heart Disease Henan Institute of Cardiovascular Epidemiology December 30 2021 Not Applicable

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Aspirin (NSC 27223) | Aspirin (NSC 27223) supplier | purchase Aspirin (NSC 27223) | Aspirin (NSC 27223) cost | Aspirin (NSC 27223) manufacturer | order Aspirin (NSC 27223) | Aspirin (NSC 27223) distributor